Novel Noninvasive Techniques to Study Neutrophil Airway Inflammation in an Ozone Challenge Model

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00743704
Recruitment Status : Completed
First Posted : August 29, 2008
Last Update Posted : April 21, 2009
Information provided by:
Fraunhofer-Institute of Toxicology and Experimental Medicine

Brief Summary:
The primary objective of this pilot study is to establish a model of neutrophil airway inflammation for future testing of anti-inflammatory substances in an early stage of clinical development. Moreover, the suitability of an electronic nose for early detection and diagnosis of airway inflammation will be determined.

Condition or disease Intervention/treatment Phase
Healthy Subjects Other: ozoneexposure Not Applicable

Detailed Description:

Experimental ozone exposure of human subjects is known to induce transient neutrophilic airway inflammation with sputum neutrophilia and elevated concentrations of inflammatory mediators in bronchoalveolar lavage and sputum supernatants. In this study, ozone at a concentration of 250 ppb will be inhaled for three hours in an ozone challenge chamber.

In a recent study, ozone challenge has been discussed as a model for pulmonary diseases dominated by neutrophilic inflammation such as COPD, providing the possibility to test new anti-inflammatory substances in early stages of clinical development.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Novel Noninvasive Techniques to Study Neutrophil Airway Inflammation in an Ozone Challenge Model
Study Start Date : August 2008
Actual Primary Completion Date : March 2009
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ozone
U.S. FDA Resources

Intervention Details:
    Other: ozoneexposure
    subjects will be exposed to either ozone (250 ppb) or filtered air in an ozone challenge chamber for three hours. Ventilation will be increased to 20 l/min/m2 by intermittent exercise on a bicycle ergometer.

Primary Outcome Measures :
  1. Change of smellprints in exhaled breath [ Time Frame: at the end of ozone exposure and 6 h and 24 h after the start of challenge compared with baseline and exposure to filtered air ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Able and willing to give written informed consent
  • Healthy male and female nonsmokers, aged 18 to 55 years, with a history of less than 1 packyear having been nonsmokers for at least the last five years, FEV1 ≥ 80 % of predicted, FEV1/FVC ≥ 70 %
  • Available to complete all study measurements
  • Women will be considered for inclusion if they are:

    • Not pregnant, as confirmed by pregnancy test, and not nursing
    • Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal, with documented proof of hysterectomy or tubal ligation, or meet clinical criteria for menopause and has been amenorrhoeic for more than 1 year prior to the screening visit)
    • Of childbearing potential and using a highly effective method of contraception during the entire study (vasectomised partner, sexual abstinence - the lifestyle of the female should be such that there is complete abstinence from intercourse from two weeks prior to the study until at least 72 hours after the end of the study -, implants, injectables, combined oral contraceptives, hormonal IUDs)
  • Subjects must be able to produce adequate sputum
  • Subjects must be responsive to ozone in a screening challenge (250 ppb, 3h) defined by a ≥ 10 % increase in sputum neutrophils 6 h after the start of ozone exposure

Exclusion Criteria:

  • Upper or lower respiratory tract infection in the last four weeks prior to screening
  • Subjects with a positive skin prick test to common aeroallergens will be excluded
  • Past or present disease, which as judged by the investigator, may affect the outcome of the study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, psychiatric disease, endocrine disease, infectious disease, inflammatory disease or pulmonary disease (including but not confined to asthma, tuberculosis, bronchiectasis or cystic fibrosis)
  • Regular intake of any prescribed or over the counter medication. Exceptions include paracetamol for pain relief, oral contraceptive medication, hormonal replacement therapy, dietary and vitamin supplements
  • Participation in another clinical trial 30 days prior to enrolment
  • Administration of corticosteroids within the last 4 weeks prior to screening
  • History of drug or alcohol abuse
  • Suspected inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00743704

Fraunhofer-Institut für Toxikologie und Experimentelle Medizin
Hannover, Niedersachsen, Germany, 30625
Sponsors and Collaborators
Fraunhofer-Institute of Toxicology and Experimental Medicine
Principal Investigator: Jens Hohlfeld, MD Fraunhofer ITEM

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jens Hohlfeld, MD, Fraunhofer-Institute of Toxicology and Experimental Medicine Identifier: NCT00743704     History of Changes
Other Study ID Numbers: 08/04 Ozelot
First Posted: August 29, 2008    Key Record Dates
Last Update Posted: April 21, 2009
Last Verified: April 2009

Additional relevant MeSH terms:
Pathologic Processes